At a glance

  • Scientists mapped gene expression and cell behavior in response to perturbations such as changes in the microbiome and inflammation.

  • Findings point to remarkable regional structure across different segments within small and large intestine.

  • Approach represents new way to study cross talk between gut epithelial cells, structural cells, and immune system in disease and health.

The intestine maintains an exquisitely delicate balance in the body, absorbing nutrients and water while also ensuring a healthy relationship with the gut microbiome — the constellation of microorganisms that reside in the human gut, regulating its function in myriad ways that affect health and disease.

This precarious equilibrium can be disrupted in conditions such as celiac disease, ulcerative colitis, or Crohn’s disease, leading to aberrant immune response and inflammation. Yet scientists don’t fully understand how different regions of the intestine resist or adapt to changes in the environment and how disease disrupts that ability.

Get more HMS news here

Now, Harvard Medical School researchers at the Broad Institute of MIT and Harvard and Massachusetts General Hospital have analyzed the entire mouse intestine, creating a map of gene expression and cell behavior by location in response to various perturbations such as microbiome changes, inflammation, and circadian rhythms.

The work reveals tight regulation of cell types and states in different regions of the organ, as well as a unique segment of the colon that is controlled by immune signals.

The findings, published Nov. 20 in Nature, showcase the remarkable adaptability and resilience of the intestine and highlight the importance of considering how cell processes are regulated and vary across different parts of a tissue or organ.

“We’ve built a blueprint of the entire gut, and that’s a remarkable achievement,” said study senior author Ramnik Xavier, the HMS Kurt J. Isselbacher Professor of Medicine in the Field of Gastroenterology at Mass General and director of the Broad Institute’s Immunology Program.

“We now have a way of studying the whole organ; examining the effect of genetic variants and immune responses associated with diet, the microbiome, and gastrointestinal disease; and designing many other experiments,” he said.

The intestine, and in particular the colon, has been studied for decades, but this approach marks a completely novel way of characterizing the organ, the researchers said.

“This work illustrates that you really have to integrate the spatial relationships governing a given organ into your thinking,” said Toufic Mayassi, co-first author on the study along with Chenhao Li, both of whom are postdoctoral researchers in the Xavier lab. “We hope our study provides a platform and framework that helps put both previous and future discoveries in context.”

Mapping the intestine

Many previous studies of the gut looked at cells or organ-like assemblies of cells in a dish. While such approaches provide a controlled environment to study the function of specific genetic variants involved in disease, they don’t illustrate how cells from different parts of an intact organ interact to bring about disease.

In 2021, Mayassi, who spent his PhD studying immune responses in the intestine, teamed up with Li, a computational biologist, to build a comprehensive map of gene expression across the entire mouse small intestine and colon using spatial transcriptomics and computational approaches.

A model of intestinal tissue looks like a gray spiral with some cells highlighted in yellow, red, or blue.
A map showing the distribution of different structural cell types in the colon. Fibroblasts are labeled in red, enterocytes in blue, and goblet cells in yellow. Image: Xavier Lab

To the researchers’ surprise, the spatial composition of the intestine — the relative location of various cell types and the genes they express — remained relatively stable when certain factors changed. It stayed the same in animals with intact and depleted gut microbiota as well as in tissue collected at night or during the day, suggesting that neither the microbiome nor circadian rhythms impacted the spatial landscape.

The intestine also showed remarkable signs of resilience. When Mayassi treated the animals with a molecule known to induce inflammation, gene expression and cell spatial distribution changed but showed signs of returning to normal one month later and had almost entirely recovered by three months.

The findings suggest that the gut’s ability to bounce back from changes brought about by inflammation could be critical to intestinal health and function.

“As a computational biologist, it is exciting to be involved in generating and exploring such a unique dataset,” Li said. “It opens the door to developing tools for analyzing spatial data and informs the design of future studies on the small and large intestine.”

Immune control

Though the intestine remained stable during many influences, unique niches within the organ were affected by gut microbiota and showed signs of adaptation.

Mice that had a normal microbiome expressed unique genes in a specific region of the colon compared to germ-free mice. Using single-cell RNA sequencing, the authors found that the changes occurred in three structural cell types. In particular, goblet cells — cup-shaped cells that secrete protective mucus — expressed those genes only in the presence of ILC2s, a kind of immune cell.

Next, the researchers plan to apply their method to study how other factors — including sex, diet, food allergies, and genetic risk factors for conditions such as inflammatory bowel disease — impact the intestine’s spatial landscape. They also hope to elucidate the extent to which the findings in mice correlate with spatial control in the human gut.

Adapted from a Broad Institute news release.

Authorship, funding, disclosures

Additional authors include Åsa Segerstolpe, Eric M. Brown, Rebecca Weisberg, Toru Nakata, Hiroshi Yano, Paula Herbst, David Artis, and Daniel B. Graham.

This work was supported in part by the Center for the Study of Inflammatory Bowel Disease, National Institutes of Health (grants RC2 DK135492, P30 DK043351, DK126871, AI151599, AI095466, AI095608, AR070116, AI172027, DK132244, K99AI180354), The Leona M. and Harry B. Helmsley Charitable Trust, Klarman Cell Observatory, Jill Roberts Institute for Research in IBD, Kenneth Rainin Foundation, Sanders Family Foundation, Rosanne H. Silbermann Foundation, Linda and Glenn Greenberg, and Allen Discovery Center Program, a Paul G. Allen Frontiers Group advised program of the Paul G. Allen Family Foundation.

Xavier is a co-founder of Jnana Therapeutics, board director at MoonLake Immunotherapeutics, and a consultant to Nestlé, and serves on the advisory board of Magnet Biomedicine. These organizations had no role in the study.